Study of P-tau217 Blood Test Impact on Early Care for Patients Over 50 with Cognitive Complaints in Primary and Specialty Medical Settings

What this Trial Is About

This research aims to evaluate how P-tau217 blood biomarker testing influences early evaluation and management of patients who present with cognitive complaints. The study focuses on comparing patient management actions between an interventional group receiving the biomarker test and a control group receiving standard care. Both primary care physicians and secondary or tertiary care specialists participate to assess the impact of testing on clinical decisions. Participants are divided into two groups based on their healthcare provider type. Patients in the interventional group undergo P-tau217 blood biomarker testing, while those in the control group receive standard care without the specific biomarker test. The study stratifies participants by whether their doctors are primary care physicians or secondarytertiary specialists, to observe differences in management actions across these care levels. Throughout the study, researchers track various outcomes including the proportion of patients with management actions taken, timing of referrals, counseling, and initiation of Alzheimers disease or other therapies. These measures are assessed at 6 and 12 months to understand the impact of biomarker testing on care pathways. Participants provide informed consent and undergo blood sampling, with ongoing monitoring to ensure adherence and completion over the study duration ending in October 2027.

A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint